Specific lineage transition of tumor-associated macrophages elicits immune evasion of ascitic tumor cells in gastric cancer with peritoneal metastasis

Yilin Li,Lei Jiang,Yang Chen,Yanyan Li,Jiajia Yuan,Jialin Lu,Zizhen Zhang,Shengde Liu,Xujiao Feng,Jiaxin Xiong,Yan Jiang,Xiaotian Zhang,Jian Li,Lin Shen

DOI: https://doi.org/10.1007/s10120-024-01486-6

2024-03-12

Gastric Cancer

Abstract:Gastric cancer with peritoneal metastasis (PM-GC), recognized as one of the deadliest cancers. However, whether and how the tumor cell-extrinsic tumor microenvironment (TME) is involved in the therapeutic failure remains unknown. Thus, this study systematically assessed the immunosuppressive tumor microenvironment in ascites from patients with PM-GC, and its contribution to dissemination and immune evasion of ascites-disseminated tumor cells (aDTCs).

oncology,gastroenterology & hepatology

What problem does this paper attempt to address?

The problem this paper attempts to address is how tumor cells achieve immune evasion through interactions with immune cells in the tumor microenvironment (TME) in peritoneal metastasis of gastric cancer (PM-GC). Specifically, the researchers focus on how the specific lineage conversion of tumor-associated macrophages (TAMs) in ascites promotes the immune evasion of ascites-disseminated tumor cells (aDTCs).

### Background
- **Problem Background**: Peritoneal metastasis of gastric cancer (PM-GC) is a highly lethal type of cancer, and current chemotherapy and targeted therapies are ineffective. Although immunotherapy has achieved significant success in other types of cancer, its effect is limited in PM-GC patients, indicating that PM-GC has highly immunosuppressive characteristics.
- **Research Motivation**: The researchers aim to systematically evaluate the immunosuppressive tumor microenvironment in the ascites of PM-GC patients to reveal its contribution to the dissemination and immune evasion of aDTCs, thereby providing a theoretical basis for developing new immunotherapy methods.

### Research Methods
- **Sample Collection**: The study included 63 ascites samples and 43 peripheral blood samples from 51 PM-GC patients.
- **Technical Approaches**:
- Single-cell RNA sequencing (scRNA-seq) was used to analyze the interactions between aDTCs and the characteristics of the ascites TME.
- Immunophenotyping analysis (SE-iFISH) was used to detect aDTCs in ascites and circulating tumor cells (CTCs) in peripheral blood.
- The mechanisms of interaction between aDTCs and immune cells were further studied in vitro cultured aDTCs.

### Main Findings
- **Interaction Between Immune Cells and aDTCs**: The study found that immune cells in ascites interact with aDTCs, promoting their immune evasion.
- **Lineage Conversion of TAMs**: Specifically, TAMs in ascites undergo a continuous lineage conversion from high expression of cathepsin (CTShigh) to high expression of complement 1q (C1Qhigh). CTShigh TAMs initially attract metastatic tumor cells into the ascites, which eventually transform into C1Qhigh TAMs, triggering excessive proliferation and immune evasion of aDTCs.
- **Mechanism Analysis**: The researchers demonstrated that C1Qhigh TAMs significantly enhance the expression of PD-L1 and NECTIN2 on the surface of aDTCs by activating the complement pathway, thereby mediating immune evasion.

### Conclusion
- **First Discovery**: The study is the first to identify the immunosuppressive lineage conversion of TAMs from CTShigh to C1Qhigh in the ascites of PM-GC patients.
- **Potential Application**: This discovery may help develop immunotherapies targeting TAMs to improve the treatment of PM-GC.

### Graphical Abstract
- **Interaction Between Immune TME in Ascites and aDTCs**: In the TAM-dominated ascites TME, TAMs in ascites undergo a conversion from CTShigh to C1Qhigh, supporting multiple stages of aDTC dissemination, including homing, proliferation, immune evasion, and therapy resistance. In the T cell-dominated ascites TME, enriched T cells do not indicate an "immune hot" TME, as infiltrating CD8+ T cells are GZMK+ pre-exhausted cells that have lost the ability to kill tumor cells.